Previous Article | Next Article ![]()
Infection and Immunity, July 2000, p. 4108-4116, Vol. 68, No. 7
Division of Geographic Medicine and Infectious Diseases,
New England Medical Center, Tufts University School of Medicine,
Boston, Massachusetts 021111; Division
of Infectious Diseases, Tufts University School of Veterinary
Medicine, North Grafton, Massachusetts
015363; and GI Cell Biology Laboratory,
Children's Hospital and Harvard Medical School, Boston,
Massachusetts 021152
Received 7 January 2000/Accepted 1 April 2000
Cryptosporidium parvum is a significant cause of
diarrheal disease worldwide. The specific molecules that mediate
C. parvum-host cell interactions and the molecular
mechanisms involved in the pathogenesis of cryptosporidiosis are
unknown. In this study we have shown that gp40, a mucin-like
glycoprotein, is localized to the surface and apical region of invasive
stages of the parasite and is shed from its surface. gp40-specific
antibodies neutralize infection in vitro, and native gp40 binds
specifically to host cells, implicating this glycoprotein in C. parvum attachment to and invasion of host cells. We have cloned
and sequenced a gene designated Cpgp40/15 that encodes gp40
as well as gp15, an antigenically distinct, surface glycoprotein also
implicated in C. parvum-host cell interactions. Analysis of
the deduced amino acid sequence of the 981-bp Cpgp40/15
revealed the presence of an N-terminal signal peptide, a polyserine
domain, multiple predicted O-glycosylation sites, a single
potential N-glycosylation site, and a hydrophobic region at
the C terminus, a finding consistent with what is required for the
addition of a GPI anchor. There is a single copy of
Cpgp40/15 in the C. parvum genome, and this
gene does not contain introns. Our data indicate that the two
Cpgp40/15-encoded proteins, gp40 and gp15, are products of
proteolytic cleavage of a 49-kDa precursor protein which is expressed
in intracellular stages of the parasite. The surface localization of
gp40 and gp15 and their involvement in the host-parasite interaction
suggest that either or both of these glycoproteins may serve as
effective targets for specific preventive or therapeutic measures for cryptosporidiosis.
Cryptosporidium parvum,
an intestinal apicomplexan parasite, is a significant cause of
diarrheal disease worldwide (7, 36). Cryptosporidial
infection is asymptomatic or self-limiting in immunocompetent hosts,
but it may be chronic and life-threatening in immunocompromised
patients such as those with AIDS. In children in developing countries,
C. parvum infection has been reported to be associated with
persistent diarrheal disease, which may result in subsequent growth
impairment (8). Recently, this parasite has been implicated
as the causative agent of numerous outbreaks of waterborne diarrheal
disease (6). There is currently no specific therapy approved
for the treatment of cryptosporidiosis.
Infection with C. parvum is initiated by ingestion of
oocysts, which undergo excystation to release sporozoites. Sporozoites attach to and invade intestinal epithelial cells, where the parasite undergoes further intracellular development through asexual as well as
sexual cycles. Merozoites released into the lumen during the asexual
cycle can attach to and invade adjacent epithelial cells and thus
maintain intracellular replication. The molecular mechanisms involved
in the pathogenesis of cryptosporidiosis and the specific molecules
that mediate C. parvum-host cell interactions are unknown. A
number of C. parvum proteins have been implicated in
attachment and invasion and are the subject of ongoing investigation (2, 9, 18, 21, 25, 29, 31, 33, 40).
We have previously identified a monoclonal antibody (MAb), 4E9, that
neutralizes C. parvum infection and inhibits attachment in
vitro (A. M. Cevallos, N. Bhat, R. Verdon, D. H. Hamer, B. Stein, S. Tzipori, M. E. A. Pereira, G. T. Keusch, and
H. D. Ward, submitted for publication). 4E9 was found to recognize
two glycoproteins, gp40 and GP900. Immunofluorescence (IF) studies
using this MAb revealed that these glycoproteins are localized to the
surface and apical region of sporozoites and merozoites, are shed in
trails from sporozoites during gliding motility, and bind to intestinal epithelial cells. The epitope recognized by 4E9 contains
In the present study, we have characterized gp40 and cloned, sequenced,
and expressed the gene encoding it. The open reading frame (ORF)
encoding gp40 also encodes a previously described (9) 15-kDa
surface glycoprotein (gp15) (W. Strong, J. Gut, and R. Nelson, personal
communication). We have investigated the relationship between gp40 and
gp15 and present here evidence to suggest that these two glycoproteins
are proteolytic fragments of a precursor protein.
C. parvum oocysts, sporozoites, and shed
proteins.
Oocysts of the GCH1 isolate (37) were treated
with 1.75% (vol/vol) sodium hypochlorite for 10 min on ice and then
washed with Dulbecco modified Eagle medium (DMEM; Life Technologies, Grand Island, N.Y.) containing 25 mM HEPES, 100 U of penicillin per ml,
and 100 µg of streptomycin per ml. Oocysts were excysted for 1 h
at 37°C in the presence of 0.75% taurocholic acid. Sporozoites were
purified by filtration through a 2.0-µm (pore-size) Nucleopore polycarbonate filter (Costar Scientific Corp., Cambridge, Mass.).
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Molecular Cloning and Expression of a Gene Encoding
Cryptosporidium parvum Glycoproteins gp40 and gp15
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-N-acetylgalactosamine (
GalNAc) residues, which are
present in a mucin-type O-glycosidic linkage. Lectins
specific for these residues also block attachment in vitro. The gene
encoding one of these glycoproteins, GP900, a high-molecular-weight
mucin-like glycoprotein, has recently been cloned and sequenced
(2).
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Cell culture. Caco-2 (human intestinal epithelial) cells originally obtained from Hans Buller, Academic Medical Center, Amsterdam, The Netherlands (38), were designated Caco-2A and maintained by the GRASP Center Cell Culture Core facility. Cells were grown in 75-cm2 flasks in DMEM, supplemented with 10% fetal calf serum, 25 mM HEPES, penicillin (100 U/ml), and streptomycin (100 µg/ml) at 37°C and 5% CO2 as described earlier (19).
Isolation of native gp40 from shed proteins. C. parvum shed proteins were fractionated by size exclusion ultrafiltration using Centricon filters (Millipore Corp., Bedford, Mass.) with molecular weight cutoffs of 10, 50, and 100 kDa. The 10- to 50-kDa fraction was enriched in gp40 as determined by silver staining and immunoblotting with MAb 4E9.
Lectin (HPA) affinity chromatography.
GalNAc-containing
glycoproteins were isolated from C. parvum oocysts as
follows. Hypochlorite-treated oocysts (1 × 108 to
2 × 108/ml) in phosphate-buffered saline (PBS)
containing protease inhibitors (described above) were lysed by five
freeze-thaw cycles, followed by detergent extraction with 1%
octylglucoside in PBS (OGS-PBS). Detergent-soluble material was
incubated with Helix pomatia agglutinin (HPA)-agarose (EY
Laboratories, Inc., San Mateo, Calif.) in 1% OGS-PBS for 18 h at
4°C. After an extensive washing, bound proteins were eluted with 0.1 M GalNAc in 0.05% OGS-PBS.
GalNAc-containing glycoproteins were also isolated from C. parvum-infected Caco-2A monolayers as follows. Caco-2A cells were grown to confluence in 75-cm2 flasks and infected with
5 × 107 hypochlorite-treated oocysts for 12 or
18 h at 37°C. Infected cells were extracted with 1% OGS-PBS in
the presence of protease inhibitors at 4°C. Detergent-soluble
material was processed for HPA affinity chromatography as described
above. Uninfected Caco-2A cells grown at the same time under identical
conditions were processed in the same way.
Antibodies. 4E9, an immunoglobulin M (IgM) MAb was produced by immunization of mice with C. parvum sporozoites (Cevallos et al., submitted). Briefly, BALB/c mice were immunized intraperitoneally with C. parvum sporozoites, spleen cells fused with myeloma cells, and hybridomas cloned in liquid medium as previously described (41). Clones which reacted with the surface of sporozoites were identified using an IF assay. MAb CrA1, an IgA MAb against a C. parvum sporozoite surface protein (gp15) was obtained by oral immunization of mice with C. parvum sporozoites (X. Zhou, S. Tzipori, and M. R. Neutra, unpublished). Briefly, BALB/c mice were immunized intragastrically with a C. parvum sporozoite and oocyst mixture, and Peyer's patch cells were subsequently fused with mouse myeloma cells as previously described (42). C. parvum-specific IgA hybridomas were identified by enzyme-linked immunosorbent assay (ELISA) and cloned, and IgA antibodies were produced in serum-free medium.
Antisera to purified native gp40 were produced as follows. HPA-isolated glycoproteins (which are enriched in gp40) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After staining with Coomassie blue, the 40-kDa band (which was shown to represent gp40 by immunoblotting with MAb 4E9 of a parallel strip of gel transferred to nitrocellulose) was excised, lyophilized, and emulsified with complete Freund's adjuvant for the initial immunization and incomplete complete Freund's adjuvant for subsequent boosts. BALB/c mice were immunized at 3- to 4-week intervals with this material, and the presence of anti-gp40 antibodies in sera was monitored by immunoblotting of an oocyst-sporozoite antigen preparation.Immunoblot analysis, immunoprecipitation, and
immunofluorescence.
Proteins were separated by SDS-PAGE,
transferred to nitrocellulose, and then probed with MAbs 4E9 and CrA1
and anti-gp40 antisera. For MAb 4E9 and anti-gp40 antisera, horseradish
peroxidase (HRP)-conjugated goat anti-mouse IgG (heavy and light chain)
antibody (Pierce Chemical Co., Rockford, Ill.) was used as secondary
antibody. For MAb CrA1, HRP-conjugated goat anti-mouse IgA
(
-chain-specific) antibody was used as secondary antibody (Southern
Biotechnology Associates, Inc., Birmingham, Ala.). Immunoblots were
developed with SuperSignal chemiluminescent substrate (Pierce). Perfect
Protein markers, 10- to 225-kDa (Novagen, Madison, Wis.), were used as
molecular weight standards and were detected by reactivity with
HRP-conjugated S-Protein according to the manufacturer's protocol.
C. parvum in vitro infection assay. The effect of anti-gp40 antisera (diluted 1:00) obtained from two different mice on C. parvum infection of Caco-2A cells was determined using an in vitro assay as described previously (39). Briefly, oocysts (104/well) preincubated with antisera for 30 min at room temperature were incubated with Caco-2A cells (2 × 104/well) grown in 96-well tissue culture plates for 24 h at 37°C and in 5% CO2. Cells were fixed and permeabilized with methanol for 10 min at room temperature and washed three times with Tris-buffered saline. Infection was quantified by ELISA as described earlier (39). Preimmune sera were used as controls.
gp40 binding assay.
Increasing concentrations of
HPA-isolated glycoproteins or shed proteins were incubated with live or
glutaraldehyde-fixed, Caco-2A cells (grown to confluence in 96-well
plates) for 1 h at 4°C (live cells) or 2 h at 37°C (fixed
cells). The amount of gp40 present in both preparations was quantified
by comparison to known concentrations of Novagen Perfect Protein
markers in silver-stained SDS gels by scanning densitometry using
Quantity One software (Bio-Rad, Hercules, Calif.). Unbound protein was washed off and bound gp40 was detected by ELISA using anti-gp40 antisera and biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, Calif.) as primary and secondary antibodies, respectively. Ovalbumin and
-galactosidase and antibodies specific for them (Sigma) were used as controls.
N-terminal and internal peptide amino acid sequence determination. A gp40-enriched preparation obtained from shed proteins was subjected to SDS-PAGE, and transferred to a polyvinylidene difluoride membrane, which was stained with Coomassie blue. The 40-kDa band (identified as gp40 by probing an additional strip from the same membrane with MAb 4E9) was excised and processed for N-terminal amino acid microsequencing by automated Edman degradation using a Perkin-Elmer ABI 477A sequencer at the Tufts University Core Facility. The N-terminal sequence of the first five residues of the 40- and 13-kDa proteins isolated by HPA affinity chromatography was determined in a similar fashion.
To obtain amino acid sequence data from internal peptides, the 40-kDa band (which was shown to represent gp40 by immunoblotting with MAb 4E9 of a parallel strip of gel transferred to nitrocellulose) was excised from a Coomassie blue-stained SDS gel and submitted to the Harvard Microchemistry Facility, Cambridge, Mass. After in-gel tryptic digestion of the protein, sequence analysis of peptides was performed by microcapillary reverse-phase high-pressure liquid chromatography nanoelectrospray tandem mass spectrometry on a Finnigan LCQ quadrupole ion trap mass spectrometer. Two peptides, p70 and p81, were selected and analyzed by matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF-MS). These two peptides were then sequenced by Edman degradation. A high-confidence amino acid sequence (supported by the MALDI-TOF-MS results) was obtained (Table 1). The MS/MS spectra of peptides derived from native gp40 was correlated with the nucleotide and deduced amino acid sequence of Cpgp40/15 using the algorithm Sequest (4a) and programs developed at the Harvard Microchemistry Facility.
|
DNA libraries and synthetic oligonucleotides. C. parvum genomic DNA libraries derived from the GCH1, SFGH-1, and NINC isolates, as well as a sporozoite cDNA library derived from the Iowa isolate, were generously provided by Giovanni Widmer, Tufts University School of Veterinary Medicine, North Grafton, Mass., and Richard Nelson, University of California at San Francisco. The oligonucleotide primers used for PCR are shown in Table 1. Degenerate primers (synthesized by Life Technologies) were designed on the basis of the amino acid sequences of the N-terminal (pN) and two internal peptides (p70 and p81) of gp40. The degeneracy of the primers was reduced by taking into account AT-rich codon usage in C. parvum (17). Nondegenerate primers were synthesized at the Tufts University Core Facility.
PCR and DNA sequencing. DNA libraries or hypochlorite-treated, freeze-thawed oocysts were used as a source of template DNA for PCR. Conditions for PCR using degenerate primers were as follows: 95°C for 2 min; 95°C for 40 s, 37°C for 60 s, and 72°C for 50 s (5 cycles); 94°C for 40 s, 55°C for 50 s, and 72°C for 50 s (35 cycles); and 72°C for 5 min. The first five cycles were excluded for PCRs using nondegenerate primers. Reagents were used at the following final concentrations: deoxynucleoside triphosphates, 0.4 mM; degenerate primers, 1 µM; nondegenerate primers, 0.5 µM; MgCl2, 1.5 mM; and Taq DNA polymerase (Life Technologies), 50 U/ml. PCR products were cloned into the TA Cloning vectors, pCR2.1 or pCRII-TOPO (Invitrogen, Carlsbad, Calif.). Plasmids were purified using a Qiagen Miniprep Kit (Qiagen, Inc., Valencia, Calif.). DNA sequencing was performed by the dye-terminator method at the Tufts University Core Facility using a Perkin-Elmer ABI 377 sequencer.
The FASTA (28) and BLAST (1) algorithms were used to compare DNA and protein sequences to sequence databases. Analysis of nucleotide and amino acid sequences was performed with the MACVECTOR (Oxford Molecular Group, Oxford, United Kingdom) and PSORT II (15) programs. Predicted mucin-type O-glycosylation sites were identified using the NetOGlyc 2.0 program (11), and potential N-glycosylation sites were identified using the Motif program (43).Expression in E. coli.
The following three
fragments were cloned into the pET-32 Xa/LIC vector, which contains an
internal S-tag, internal and C-terminal His tags, and N-terminal Trx
tag sequences (Novagen): (i) an 891-bp fragment encoding amino acids 31 to 326 (corresponding to the entire Cpgp40/15 ORF, minus the
putative signal peptide, designated pAMC40/15; (ii) a 315-bp fragment
encoding amino acids 223 to 326 (corresponding to gp15, designated
pAMC15); and (iii) a 576-bp fragment encoding amino acids 31 to 222 (corresponding to gp40, designated pAMC40). A control insert provided
by Novagen was also cloned into the same vector. Overexpression in
Escherichia coli AD494(DE3) was induced with 1 mM IPTG
(isopropyl-
-D-thiogalactopyranoside). Fusion proteins
encoded by pAMC40/15, pAMC40, and pAMC15 were designated pepAMC40/15,
pepAMC40, and pepAMC15, respectively. pepAMC40 was toxic to E. coli; however, the transformation of E. coli AD494 was
successful when performed in the presence of the plasmid pLysS (which
encodes T7 lysozyme, a natural inhibitor of T7 RNA polymerase
[Novagen]). The S-tag present in fusion proteins was identified in
immunoblots by reactivity with HRP-conjugated S-Protein according to
the manufacturer's instructions (Novagen).
Genomic Southern analysis. Genomic DNA was extracted from a sporozoite-oocyst preparation using a G Nome DNA kit (Bio 101, Inc., Vista, Calif.). The restriction enzymes EcoRI and HindIII (New England Biolabs, Beverly, Mass.) alone or in combination were used to digest the genomic DNA. DNA fragments were separated on a 1% agarose gel, transferred to a nylon membrane (Duralon-UV; Stratagene, La Jolla, Calif.), and fixed by UV radiation using a UV Stratalinker 1800 (Stratagene). An 856-bp PCR product amplified from genomic DNA using primers 5 and 8 was used as a probe for this blot. The probe was labeled and hybridization was detected using the ECL direct nucleic acid labeling system and detection reagent (Amersham, Arlington Heights, Ill.) according to the manufacturer's instructions.
RT-PCR. Caco-2A cells were grown to confluence in six-well plates and were infected with C. parvum oocysts (106) for 24 h. RNA was extracted from uninfected and infected monolayers using the RNeasy kit (Qiagen). Contaminating DNA was removed by RNase-free DNase treatment. Then, 0.5 µg of RNA was used in each reverse transcription (RT) reaction, which was performed using primers 9 and 10 (Table 1) and the Access RT-PCR System according to the manufacturer's instructions (Promega, Madison, Wis.). RNA from uninfected Caco-2A cells was used as a negative control. RT-PCR reactions without added reverse transcriptase were performed in parallel to confirm that the PCR products were not due to the amplification of contaminating DNA. The DNA sequence of the product obtained by RT-PCR was determined as described above.
The DNA sequence of Cpgp40/15 was deposited at GenBank under accession number AF155624.| |
RESULTS |
|---|
|
|
|---|
gp40 is unrelated to GP900.
We previously identified gp40
using 4E9, an MAb which recognizes a carbohydrate epitope containing
GalNAc residues that are present on two glycoproteins, gp40 and
GP900. The presence of these
GalNAc residues was exploited to
isolate glycoproteins from C. parvum lysates by affinity
chromatography using an
GalNAc-specific lectin, HPA. Analysis of
this preparation by silver staining (Fig. 1A) and immunoblotting with MAb 4E9 (Fig.
1B, lane 1) revealed that a 40-kDa band recognized by MAb 4E9 was among
the major proteins present (bands at >900, 128, 26, and 13 kDa were
also present). In order to produce gp40-specific antibodies, native
gp40 was purified by excision of the 40-kDa band from
polyacrylamide-SDS gels and used to immunize mice. The purity of gp40
was verified by SDS-PAGE and silver staining of an aliquot of the
protein (eluted from the excised gel with sample buffer), which
revealed the presence of a single 40-kDa band (data not shown). Sera
from these mice reacted exclusively with a 40-kDa band by
immunoblotting, thus confirming the specificity of the antibody for
gp40 (Fig. 1B, lane 2). The gp40-specific antisera immunoprecipitated a
40-kDa band from C. parvum sporozoite-oocyst lysates which
was recognized by MAb 4E9 (data not shown), confirming that both
antibodies recognized the same protein. However, the anti-gp40 antisera
did not recognize GP900 (Fig. 1B, lane 2), suggesting that other than
the presence of a common carbohydrate epitope, gp40 is unrelated to
GP900.
|
gp40-specific antisera neutralize C. parvum infection
of intestinal epithelial cells.
Our previous studies showed that
MAb 4E9, which recognizes gp40 as well as GP900, neutralized infection
and blocked attachment in vitro (Cevallos et al., submitted). In order
to determine if gp40 is involved in mediating attachment and/or
invasion, we assessed the effect of the gp40-specific antisera on
C. parvum infection of intestinal epithelial cells by using
an in vitro assay (39). Compared to their respective
preimmune sera, gp40-specific antisera (from two different mice)
significantly inhibited (by 82 and 68%, respectively) C. parvum infection of Caco-2A cells (Fig.
2a). This result implicates gp40 in
C. parvum attachment to and/or invasion of host cells.
|
Native gp40 binds to intestinal epithelial cells.
Neutralization of infection by gp40-specific antisera suggested that
gp40 is involved in C. parvum attachment to and/or invasion of host cells. In order to determine if gp40 bound to host cells, HPA-isolated glycoproteins or shed proteins (both of which are enriched
in gp40) were incubated with live or glutaraldehyde-fixed Caco-2A
cells, and gp40 binding was quantified by ELISA using gp40-specific
antisera. As shown in Fig. 2b, binding of gp40 (present in both
preparations) to Caco-2A cells occurred in a dose-dependent and
saturable manner. There was no significant binding of the control
proteins,
-galactosidase (Fig. 2b), or ovalbumin (not shown).
Similar results were obtained with live as well as fixed cells (not
shown). These results further implicate gp40 in sporozoite attachment
to and/or invasion of host cells.
Cloning, sequencing, and analysis of the gene encoding gp40. We set out to clone and sequence the gene encoding gp40. Our strategy was to ascertain the N-terminal and internal amino acid sequences from two internal tryptic peptides of native gp40 (purified from shed proteins by size exclusion ultrafiltration and gel isolation) and to design degenerate PCR primers based on these peptide sequences to amplify the gene encoding gp40. The sequences of the N-terminal six amino acids and two internal tryptic peptides, designated p70 and p81, are shown in Table 1. Comparison of these sequences with the deduced amino acid sequence of GP900 (2) revealed no significant similarity, confirming that these two proteins are unrelated. In addition, BLAST searches (1) with these sequences did not reveal significant similarity with known proteins in the databases. The sequence of the N-terminal five amino acids of gp40 isolated by HPA affinity chromatography was also determined and found to be identical to that isolated from shed proteins, confirming that both preparations contained the same protein.
The multiple PCR steps that we used to clone the gene encoding gp40 are shown in Fig. 3a. Using degenerate primers 2 and 3 based on the amino acid sequence of internal peptides p70 and p81 (Table 1), a 78-bp fragment was amplified from oocyst genomic DNA, cloned into the pCR 2.1 vector, and sequenced. Using primer 4 (based on the nucleotide sequence of the 78-bp fragment) and degenerate primer 1 (based on the amino acid sequence of the N-terminal peptide) a 450-bp product was amplified from the same oocyst genomic DNA, cloned, and sequenced. The deduced amino acid sequences of the 78- and 450-bp fragments matched those of the known peptide sequences from the native protein. Primers 5 and 6 (based on the nucleotide sequence of the 450-bp fragment) were used to screen six C. parvum genomic and cDNA libraries by PCR. A product of the expected size (226 bp) was amplified from all of the libraries tested (data not shown). Anchored PCR of one of these libraries (GCH1; genomic DNA in
ZapII)
was used to obtain the sequences 5' and 3' of the 450-bp fragment.
Thus, DNA from this library was used as template for PCR with primers
based on the sequence of the T7 promoter of the
ZapII phage vector
(primer T7) and the 450-bp fragment (primer 5). The resulting 861-bp
product amplified by PCR was sequenced. A similar approach with primer
6 was used to obtain a 703-bp product. Assembly and analysis of these
overlapping fragments revealed a 981-bp ORF. Subsequently, to confirm
our sequence, a 1,223-bp fragment was amplified by PCR from oocyst (GCH1) genomic DNA, using primers 7 and 8, along with a high-fidelity polymerase Pfu (Stratagene), and cloned into the Topo pCR II
vector. Four independently derived clones were sequenced to correct
potential PCR errors. BLAST comparison of the DNA and deduced amino
acid sequences with protein and DNA sequence databases did not reveal significant similarity with any known genes or proteins.
|
The gene encoding gp40 is present in single copy and does not
contain introns.
Southern blot analysis of genomic DNA isolated
from GCH1 oocysts using an 856-bp Cpgp40/15 probe indicated
that this sequence is present in single copy in the C. parvum genome. As seen in Fig. 4a,
this probe hybridized to a single ~800-bp
EcoRI/HindIII restriction fragment of the
expected size. When genomic DNA was digested with EcoRI
alone, the probe hybridized to a single 23-kb fragment.
|
The gene encoding gp40 also encodes gp15.
In an independent
study, IgA MAbs CrA1 and CrA2 which recognize a previously identified
15-kDa surface glycoprotein (9) were used to isolate a clone
from a genomic DNA expression library (Strong et al., personal
communication). Analysis of the DNA sequence of this clone revealed
that it was almost identical to that of the gene identified in the
present study. We therefore investigated the possibility that the gene
encoding gp40 also encoded a 15-kDa protein (named gp15) as well.
Previous studies indicated that gp15 bound the lectin HPA
(9), suggesting that this protein may be present in the
HPA-isolated glycoprotein preparation used to purify native gp40.
Analysis of this preparation by SDS-PAGE and immunoblotting with MAb
CrA1 revealed that a 13-kDa protein recognized by MAb CrA1 (indicating
that this band represents gp15) was indeed present (Fig. 1A, lane 3;
Fig. 5B, lane 4). We therefore obtained
N-terminal amino acid sequence of the 13-kDa band from this
preparation. The results indicated that the N-terminal residues ETSEA
corresponded to amino acid residues 223 to 227 of the deduced amino
acid sequence of the gene encoding gp40 (Fig. 3b). This finding,
together with the work of Strong et al. (personal communication), indicates that gp15 is encoded by the same gene as gp40. Therefore, we
have designated this gene Cpgp40/15.
|
gp40 and gp15 are antigenically distinct proteins encoded by the
same gene.
To characterize the relationship between gp40 and gp15,
we determined whether antibodies to gp40 and gp15 cross-reacted with gp15 and gp40, respectively, by immunoblotting of various C. parvum preparations, including oocysts, sporozoites, and shed
proteins. As shown in Fig. 5, in all of the antigen preparations
tested, the anti-gp40 antisera only recognized gp40 and did not react with gp15 (confirming the specificity of the antibody for gp40). Similarly, MAb CrA1 only recognized gp15 and not gp40. In addition there was no difference in the Mr value of
either protein under reducing or nonreducing conditions (data not
shown). To further corroborate these findings, we overexpressed
fragments of Cpgp40/15 encoding amino acids 31 to 326 (pepAMC40/15), amino acids 31 to 222 (pepAMC40), and amino acids 223 to
326 (pepAMC15) as thioredoxin fusion proteins in E. coli.
These were probed with gp40- and gp15-specific antibodies. The results
showed that both antibodies reacted with the fusion protein encoded by
the entire ORF (Fig. 6B and C, lanes 2).
However, the anti-gp40 antibody reacted only with pepAMC40 (Fig. 6C,
lane 4), and MAb CrA1 reacted only with pepAMC15 (Fig. 6B, lane 3).
These results confirm that gp40 and gp15 are antigenically distinct
proteins encoded by the same gene Cpgp40/15.
|
gp40 and gp15 are differentially localized in C. parvum
sporozoites.
The localization of gp40 and gp15 in C. parvum developmental stages was determined by IF using antibodies
specific for both proteins. The anti-gp40 antisera reacted mainly with
the surface of the anterior portion of sporozoites, suggestive of an
apical complex localization (Fig. 7A). In
the intracellular stages, there was reactivity with the entire surface
and apical region of merozoites (present within meronts) in infected
Caco-2A cells (Fig. 7B). In contrast, gp15 was present on the entire
surface of sporozoites (Fig. 7C) as well as merozoites (Fig. 7D). These
results suggest that these two proteins are differentially localized in
sporozoites.
|
gp40 and gp15 are products of proteolytic cleavage of a 49-kDa
precursor protein.
The finding that gp40 and gp15 are encoded by
the same gene raised the possibility that they may be proteolytic
fragments of a larger precursor protein. Immunoblotting of oocysts,
sporozoites, shed proteins, and HPA-isolated glycoproteins with
anti-gp40 antisera and MAb CrA1, however, did not reveal the presence
of a putative precursor protein (Fig. 1B, lane 2, and Fig. 5). We
therefore sought to determine whether a putative precursor protein was
expressed by intracellular stages of the parasite. To do this, we
infected Caco-2A cells with oocysts for 12 or 18 h, isolated
GalNAc-containing glycoproteins from them by HPA affinity
chromatography, and analyzed them by immunoblotting with anti-gp40
antisera and MAb CrA1. This revealed the presence of a 49-kDa protein
which was recognized by both antibodies (Fig. 8A and
B, lanes 2) in addition to a 40-kDa band
recognized only by anti-gp40 antisera (Fig. 8A, lane 2) and a ~13-kDa
band recognized only by MAb CrA1 (Fig. 8B, lane 2). Similar results
were obtained at both time points (not shown). The 49-kDa band was not
detected by either antibody in glycoproteins isolated in the same way
from uninfected cells (Fig. 8A and B, lanes 1). These results implicate
the 49-kDa protein recognized by both antibodies as the precursor of
gp40 and gp15 and confirm that these two polypeptides are proteolytic
fragments of the same protein.
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study we have cloned a C. parvum gene, Cpgp40/15, which encodes two antigenically distinct polypeptides, gp40 and gp15. These two glycoproteins are the products of cleavage of a 49-kDa precursor protein. gp40, a mucin-like glycoprotein was previously identified using a neutralizing MAb, 4E9, to a carbohydrate epitope present on gp40, as well as another glycoprotein (GP900). In the present study we have shown that other than the presence of a common carbohydrate epitope, gp40 is unrelated to GP900. gp40 is localized to the surface and apical region of invasive stages of the parasite and is shed from its surface. gp40-specific antisera neutralize infection in vitro, and native gp40 binds to host cells, implicating this protein in C. parvum attachment to and/or invasion of host cells. A recent study described the presence of a ~47-kDa membrane-associated protein localized to the apical region of C. parvum sporozoites, which also bound to intestinal epithelial cells (25). The relationship of this protein to gp40 remains to be determined.
gp15 was identified by two groups of investigators. Gut and Nelson
described a 15-kDa C. parvum glycoprotein using an MAb, 11A5, to a carbohydrate epitope (9). Interestingly, this
protein is also present in sporozoites and merozoites, contains
GalNAc residues, and is shed in trails during the gliding movement
of sporozoites. A 15-kDa protein was also identified using an IgA MAb,
CrA1, which was obtained by oral immunization of mice with C. parvum (Zhou et al., unpublished). This MAb, which is directed against a protein epitope, is partially protective against C. parvum infection in a "backpack" tumor gamma
interferon-preconditioned scid mouse model (Tzipori and
Neutra, unpublished). Cross-immunoprecipitation studies revealed that
these two MAbs recognized the same 15-kDa protein, (Strong et al.,
personal communication). Other investigators have also described 15-kDa
proteins in C. parvum sporozoites (16, 17, 20,
34), two of which have been cloned and sequenced (16, 17,
20). However, there is no similarity in the deduced amino acid
sequences of these proteins with that of gp15. The short hydrophobic
stretch at the C-terminal region of gp15 is consistent with the signal
required for the addition of a GPI anchor, suggesting that gp15 may be
anchored in the membrane by this type of linkage. A number of parasite
proteins, including those which are shed from the surface, are known to
be GPI anchored (22, 23, 30, 35).
The molecular masses of the two Cpgp40/15-encoded proteins,
as determined by SDS-PAGE and comparison to Novagen Perfect Protein markers, are 40 and 13 kDa. However, analysis of the deduced amino acid
sequence of Cpgp40/15 predicts a mass of 20 kDa for gp40 (excluding the putative signal peptide) and a mass of 11 kDa for gp15.
This discrepancy suggests that the additional mass present in the
native proteins may be accounted for by glycosylation. This possibility
is likely in view of several predicted mucin type
O-glycosylation sites in the deduced amino acid sequence and
is in keeping with our previous biochemical findings of terminal
GalNAc residues (which are present on oligosaccharides
O-glycosidically linked to serine or threonine residues) in
gp40 (Cevallos et al., submitted). Most of the predicted sites of
O-glycosylation in gp40 are present in a polyserine domain
in the N-terminal region of the deduced amino acid sequence. A
serine-rich motif is also present in the sequence of TRAP C-1, another
C. parvum protein which is implicated in attachment and
invasion (33). Although TRAP C-1 has not been reported to be
glycosylated, analysis of the deduced amino acid sequence using
NetOGlyc 2.0 predicts several sites of mucin-type
O-glycosylation. None of the serine or threonine residues in
gp15 are predicted to be sites of mucin type
O-glycosylation. However, lectin-binding studies suggest the
presence of O-linked
GalNAc residues in this protein (9).
We have previously also shown the presence of these
GalNAc residues
in GP900 (Cevallos et al., submitted for publication), a C. parvum surface glycoprotein, which contains polythreonine
mucin-like domains and has been shown to mediate invasion
(2). Our previous findings that lectins specific for
GalNAc residues block attachment in vitro implicate these glycans as
playing a role in adhesion. These glycans may mediate attachment by
direct binding to host carbohydrate-binding proteins or by functioning
as a "bridge" between host and parasite carbohydrate-binding
proteins. The latter possibility may be likely in view of our earlier
finding of a Gal/GalNAc-specific sporozoite lectin which may be
involved in mediating attachment to host cells (18, 19).
Mucin-like proteins in other protozoa, such as Trypanosoma cruzi, are also shed from the surface and are implicated in
mediating attachment to host cells (30).
In this study we have shown that Cpgp40/15 encodes two antigenically distinct polypeptides, gp40 and gp15. We have identified the regions of the gene encoding each protein by determining their respective N-terminal amino acid sequences. There is no similarity in the deduced amino acid sequences of gp40 and gp15, a finding which is consistent with the finding that antibodies specific for each protein reacted exclusively with the corresponding native or recombinant proteins. In addition, the recombinant fusion protein generated by in-frame expression of the entire Cpgp40/15 sequence is recognized by antibodies specific for both gp40 and gp15. However, fusion proteins encoded by sequences upstream and downstream of the experimentally determined N terminus of gp15 are recognized exclusively by antibodies specific for either gp40 or gp15, respectively. These data are consistent with the finding that gp40 and gp15 are products of proteolytic cleavage of a 49-kDa putative precursor protein which is recognized by antibodies to both gp40 and gp15.
The putative precursor was detected only in actively replicating intracellular stages of the parasite and not in the metabolically quiescent oocyst or sporozoite stages, suggesting that the protein is synthesized during the intracellular asexual cycle. It is not known at which stage in the life cycle cleavage of the precursor occurs. The differential localization of gp40 and gp15 in sporozoites by IF suggests that cleavage occurs in vivo in the parasite. The protease responsible for the cleavage of the precursor is also not known and may be of parasite or host origin. A serine protease, a cysteine protease, and an arginine aminopeptidase have been reported to be present in C. parvum (5, 24, 27). However, it remains to be determined whether any of these enzymes are involved in processing of the precursor protein.
Proteolytic cleavage of a precursor protein yielding polypeptides involved in adhesion or invasion has been described in other apicomplexan parasites. For example, Plasmodium merozoite surface proteins involved in the invasion of red cells are derived from proteolytic cleavage of MSP-1, a 200-kDa precursor protein that is synthesized during schizogony (3, 12-14). Posttranslational processing generates fragments of 83, 42, 38, and 28 to 30 kDa, which remain as a noncovalently linked complex on the surface of the merozoite. The 42-kDa protein is further cleaved to produce a 19-kDa C-terminal fragment at the time of invasion, and the other fragments are shed during this process. Toxoplasma rhoptry proteins secreted during the invasion process are also synthesized as pro-proteins, which are processed in the nascent rhoptries of dividing parasites (4, 32).
A number of findings suggest that gp40 and gp15 are involved in C. parvum-host cell interactions. Native gp40 binds to host cells and gp40-specific antisera neutralize infection in vitro. Previous studies have shown that a gp15-specific IgA MAb (CrA1) neutralizes infection in vivo (Tzipori and Neutra, unpublished). The apical and surface localization of gp40 and gp15 in invasive stages of the parasite and the finding that they are shed from the surface are consistent with a role in attachment and invasion. The likely involvement of these C. parvum proteins in the initial host-parasite interaction suggests a basis for devising strategies to inhibit this interaction. Either gp40, gp15, or both of these glycoproteins may serve as effective targets for specific preventive or therapeutic measures for cryptosporidiosis.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by Public Health Service grants U19 AI33384, P30 DK34928 (GRASP Digestive Diseases Center), and P30 DK34854 (Harvard Digestive Diseases Center).
We gratefully acknowledge Giovanni Widmer and Richard Nelson for providing DNA libraries and for helpful discussions; Bill Strong, Jiri Gut, and Richard Nelson for sharing data prior to publication; Mike Berne, Tufts University School of Medicine Core facility, for N-terminal amino acid sequencing, DNA sequencing, and oligonucleotide synthesis; Bill Lane, Harvard Microchemistry Facility, for internal peptide sequencing, MS/MS analysis, and helpful discussions; Anne Kane, GRASP Intestinal Microbiology Core, for providing microbiological media and for helpful discussions; Doug Jefferson, GRASP Cell Culture Core, for providing Caco-2A cells; and members of the Waldor laboratory, Shiv Pillai and Miercio Pereira, for helpful discussions.
| |
ADDENDUM IN PROOF |
|---|
Since the submission of this paper, Priest et al. (J. W. Priest, J. P. Kwon, M. J. Arrowood, and P. J. Laramie, Mol. Biochem. Parasitol. 106:261-271, 2000) have reported the cloning of a gene encoding the immunodominant 17-kDa antigen from Cryptosporidium parvum. The nucleotide sequence of this gene is very similar to that of Cpgp40/15.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: New England Medical Center, Division of Geographic Medicine and Infectious Diseases, 750 Washington St., NEMC Box 041, Boston, MA 02111. Phone: (617) 636-7032. Fax: (617) 636-5292. E-mail: hward{at}lifespan.org.
Editor: W. A. Petri Jr.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402 |
| 2. | Barnes, D. A., A. Bonnin, J. X. Huang, L. Gousset, J. Wu, J. Gut, P. Doyle, J. F. Dubremetz, H. Ward, and C. Petersen. 1998. A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion. Mol. Biochem. Parasitol. 96:93-110[CrossRef][Medline]. |
| 3. | Blackman, M., and A. Holder. 1992. Secondary processing of the Plasmodium falciparum merozoite surface protein (MSP-1) by a calcium-dependent membrane bound serine protease: shedding of MSP-133 as a non-covalently associated complex with other fragments of MSP-1. Mol. Biochem. Parasitol. 50:307-316[CrossRef][Medline]. |
| 4. | Bradley, P. J., and J. C. Boothroyd. 1999. Identification of the pro-mature processing site of Toxoplasma ROP1 by mass spectrometry. Mol. Biochem. Parasitol. 100:103-109[CrossRef][Medline]. |
| 4a. | Eng, J., A. L. McCormack, and J. R. Yates, III. 1994. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5:976-989[CrossRef]. |
| 5. | Forney, J. R., S. Yang, and M. C. Healey. 1996. Protease activity associated with excystation of Cryptosporidium parvum oocysts. J. Parasitol. 82:889-892[CrossRef][Medline]. |
| 6. | Fricker, C. R., and J. H. Crabb. 1998. Water-borne cryptosporidiosis: detection methods and treatment options. Adv. Parasitol. 40:241-278[Medline]. |
| 7. | Griffiths, J. K. 1998. Human cryptosporidiosis: epidemiology, transmission, clinical disease, treatment, and diagnosis. Adv. Parasitol. 40:37-85[Medline]. |
| 8. | Guerrant, R. L. 1997. Cryptosporidiosis: an emerging, highly infectious threat. Emerg. Infect. Dis. 3:51-57[Medline]. |
| 9. | Gut, J., and R. G. Nelson. 1994. Cryptosporidium parvum sporozoites deposit trails of 11A5 antigen during gliding locomotion and shed 11A5 antigen during invasion of MDCK cells in vitro. J. Eukaryot. Microbiol. 41:42S-43S[Medline]. |
| 10. |
Hamer, D. H.,
H. D. Ward,
S. Tzipori,
M. E. Pereira,
J. P. Alroy, and G. T. Keusch.
1994.
Attachment of Cryptosporidium parvum sporozoites to MDCK cells in vitro.
Infect. Immun.
62:2208-2213 |
| 11. | Hansen, J. E., O. Lund, N. Tolstrup, A. A. Gooley, K. L. Williams, and S. Brunak. 1998. NetOglyc: prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconj. J. 15:115-130[CrossRef][Medline]. |
| 12. |
Holder, A. A., and R. R. Freeman.
1984.
The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor.
J. Exp. Med.
160:624-629 |
| 13. | Holder, A. A., M. J. Lockyer, K. G. Odink, J. S. Sandhu, V. Riveros-Moreno, S. C. N. Hillman, L. S. Davi, M. L. V. Tizard, R. T. Schwarz, and R. R. Freeman. 1985. Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature 317:270-273[CrossRef][Medline]. |
| 14. | Holder, A. A., J. S. Sandhu, Y. Hillman, L. S. Davey, S. C. Nicholls, H. Cooper, and M. J. Lockyer. 1987. Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum. Parasitology 94:199-208. |
| 15. | Horton, P., and K. Nakai. 1997. Better prediction of protein cellular localization sites with the k nearest neighbors classifier. Ismb 5:147-152. |
| 16. | Jenkins, M. C., and R. Fayer. 1995. Cloning and expression of cDNA encoding an antigenic Cryptosporidium parvum protein. Mol. Biochem. Parasitol. 71:149-152[CrossRef][Medline]. |
| 17. | Jenkins, M. C., and C. Petersen. 1997. Molecular biology of Cryptosporidium, p. 225-232. In R. Fayer (ed.), Cryptosporidium and cryptosporidiosis. CRC Press, Boca Raton, Fla. |
| 18. | Joe, A., D. H. Hamer, M. A. Kelley, M. E. Pereira, G. T. Keusch, S. Tzipori, and H. D. Ward. 1994. Role of a Gal/GalNAc-specific sporozoite surface lectin in Cryptosporidium parvum-host cell interaction. J. Eukaryot. Microbiol. 41:44S[Medline]. |
| 19. |
Joe, A.,
R. Verdon,
S. Tizpori,
G. T. Keusch, and H. D. Ward.
1998.
Attachment of Cryptosporidium parvum sporozoites to human intestinal epithelial cells.
Infect. Immun.
66:3429-3432 |
| 20. | Khramtsov, N. V., B. Oppert, B. A. Montelone, and S. J. Upton. 1997. Sequencing, analysis and expression in Escherichia coli of a gene encoding a 15-kDa Cryptosporidium parvum protein. Biochem. Biophys. Res. Commun. 230:164-166[CrossRef][Medline]. |
| 21. |
Langer, R., and M. Riggs.
1999.
Cryptosporidium parvum apical complex glycoprotein CSL contains a sporozoite ligand for intestinal epithelial cells.
Infect. Immun.
67:5282-5291 |
| 22. |
Manger, I. D.,
A. B. Hehl, and J. C. Boothroyd.
1998.
The surface of Toxoplasma tachyzoites is dominated by a family of glycosylphosphatidylinositol-anchored antigens related to SAG1.
Infect. Immun.
66:2237-2244 |
| 23. | McConville, M. J., and A. J. Ferguson. 1993. The structure, biosynthesis and function of glycosylated phosphatidylinositols in the parasitic protozoa and higher eukaryotes. Biochem. J. 249:305-324. |
| 24. | Nesterenko, M. V., M. Tilley, and S. J. Upton. 1995. A metallo-dependent cysteine proteinase of Cryptosporidium parvum associated with the surface of sporozoites. Microbios 83:77-88[Medline]. |
| 25. | Nesterenko, M. V., K. Woods, and S. J. Upton. 1999. Receptor/ligand interactions between Cryptosporidium parvum and the surface of the host cell. Biochim. Biophys. Acta 1454:165-173[Medline]. |
| 26. |
Nielsen, H.,
J. Engelbrecht,
S. Brunak, and G. von Heijne.
1997.
Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites.
Protein Eng.
10:1-6 |
| 27. |
Okhuysen, P. C.,
H. L. DuPont,
C. R. Sterling, and C. L. Chappell.
1994.
Arginine aminopeptidase, an integral membrane protein of the Cryptosporidium parvum sporozoite.
Infect. Immun.
62:4667-4670 |
| 28. | Pearson, W. R. 1990. Rapid and sensitive sequence comparison with FASTP and FASTA. Methods Enzymol. 183:63-98[Medline]. |
| 29. | Riggs, M. W., A. L. Stone, P. A. Yount, R. C. Langer, M. J. Arrowood, and D. L. Bentley. 1997. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. J. Immunol. 158:1787-1795[Abstract]. |
| 30. | Schenkman, S., M. A. Ferguson, N. Heise, M. L. de Almeida, R. A. Mortara, and N. Yoshida. 1993. Mucin-like glycoproteins linked to the membrane by glycosylphosphatidylinositol anchor are the major acceptors of sialic acid in a reaction catalyzed by trans-sialidase in metacyclic forms of Trypanosoma cruzi. Mol. Biochem. Parasitol. 59:293-303[CrossRef][Medline]. |
| 31. | Schroeder, A. A., C. E. Lawrence, and M. S. Abrahamsen. 1999. Differential mRNA display cloning and characterization of a Cryptosporidium parvum gene expressed during intracellular development. J. Parasitol. 85:213-220[CrossRef][Medline]. |
| 32. | Soldati, D., A. Lassen, J. F. Dubremetz, and J. C. Boothroyd. 1998. Processing of Toxoplasma ROP1 protein in nascent rhoptries. Mol. Biochem. Parasitol. 96:37-48[CrossRef][Medline]. |
| 33. | Spano, F., L. Putignani, S. Naitza, C. Puri, S. Wright, and A. Crisanti. 1998. Molecular cloning and expression analysis of a Cryptosporidium parvum gene encoding a new member of the thrombospondin family. Mol. Biochem. Parasitol. 92:147-162[CrossRef][Medline]. |
| 34. |
Tilley, M.,
S. J. Upton,
R. Fayer,
J. R. Barta,
C. E. Chrisp,
P. S. Freed,
B. L. Blagburn,
B. C. Anderson, and S. M. Barnard.
1991.
Identification of a 15-kilodalton surface glycoprotein on sporozoites of Cryptosporidium parvum.
Infect. Immun.
59:1002-1007 |
| 35. |
Tomavo, S.,
R. T. Schwarz, and J. F. Dubremetz.
1989.
Evidence for glycosyl-phosphatidylinositol anchoring of Toxoplasma gondii major surface antigens.
Mol. Cell. Biol.
9:4576-4580 |
| 36. | Tzipori, S., and J. K. Griffiths. 1998. Natural history and biology of Cryptosporidium parvum. Adv. Parasitol. 40:6-36. |
| 37. |
Tzipori, S.,
W. Rand,
J. Griffiths,
G. Widmer, and J. Crabb.
1994.
Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin.
Clin. Diagn. Lab. Immunol.
1:450-463 |
| 38. | Van Beers, E. H., R. H. Al, E. H. Rings, A. W. Einerhand, J. Dekker, and H. A. Buller. 1995. Lactase and sucrase-isomaltase gene expression during Caco-2 cell differentiation. Biochem. J. 308:769-775. |
| 39. | Verdon, R., G. T. Keusch, S. Tzipori, S. A. Grubman, D. M. Jefferson, and H. D. Ward. 1997. An in vitro model of infection of human biliary epithelial cells by Cryptosporidium parvum. J. Infect. Dis. 175:1268-1272[Medline]. |
| 40. | Ward, H. D., and A. M. Cevallos. 1998. Cryptosporidium: molecular basis of host-parasite interaction. Adv. Parasitol. 40:151-185[Medline]. |
| 41. | Ward, H. D., A. V. Kane, E. Ortega-Barria, G. T. Keusch, and M. E. Pereira. 1990. Identification of developmentally regulated Giardia lamblia cyst antigens using GCSA-1, a cyst- specific monoclonal antibody. Mol. Microbiol. 4:2095-2102[CrossRef][Medline]. |
| 42. |
Weltzin, R. L.,
P. Lucia-Zandris,
P. Michetti,
B. N. Fields,
J. P. Kraehnbuhl, and M. R. Neutra.
1989.
Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA against enteric viral proteins.
J. Cell Biol.
108:1673-1685 |
| 43. |
Yada, T.,
Y. Totoki,
M. Ishikawa,
K. Asai, and K. Nakai.
1998.
Automatic extraction of motifs represented in the hidden Markov model from a number of DNA sequences.
Bioinformatics
14:317-325 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»